Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024623 (
gastric cancer
)
36,219
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Plasminogen activator activity was investigated in extracts of 42 surgically removed gastric carcinomas. The mean levels of total plasminogen activator (total-PA) and
urokinase-type plasminogen activator
(
u-PA
) activities in the gastric carcinomas were significantly higher than those in the background normal tissues (p less than 0.001). On electrophoresis, gastric cancers were found to contain
u-PA
as the predominant PA, this being confirmed using zymography by direct inhibition with anti-
urokinase
antibody. Assessment of the relationship between PA activity and biological behavior of
gastric cancer
revealed total-PA and
u-PA
levels to be significantly higher in differentiated than in undifferentiated tumors (p less than 0.001), and in aneuploid than in diploid ones (p less than 0.01). Immunohistochemical staining showed that the proportion of
u-PA
-positive cancer cells in the carcinoma tissues also correlated with activity as measured by the azocaseinolytic method. These findings suggest that the study of PA contents in
gastric cancer
, combined with a nuclear DNA ploidy and immunohistochemical analysis, might be useful for understanding the biological characteristics of the tumor.
...
PMID:Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining. 190 1
Ascitic fluid from tumour patients (hepatoma,
gastric cancer
, gallbladder cancer, colorectal cancer, ovarian cancer) and from non-malignant diseases (liver cirrhosis, congestive heart failure) were compared with respect to their content of determinants of the fibrinolytic system, tissue-type plasminogen activator antigen (t-PAag) and activity (t-PAact),
urokinase-type plasminogen activator
antigen (u-PA) and plasminogen activator inhibitor activity (PAI). Furthermore, SDS-polyacrylamide slab-gel electrophoresis (SDS-PAGE) was performed to evaluate molecular weight distribution of the detectable fibrinolytic parameters. In malignant ascites, PAI activity was three to four times higher, and increased complex formation of PAI with t-PA could be demonstrated, compared with non-malignant ascitic fluid. Tissue-type plasminogen activator antigen and activity showed a similar concentration in ascites of both study groups.
Urokinase-type plasminogen activator
antigen was detectable neither in ascites of malignant nor in ascites of non-malignant origin. It is concluded that t-PA is the physiological plasminogen activator in ascites and that increased PAI levels followed by increased complex formation between t-PA and PAI might reflect a reaction of the peritoneum.
...
PMID:Plasminogen activators and plasminogen activator inhibitor in malignant and non-malignant ascitic fluid. 285 12
Three cases of multicentric reticulohistiocytosis showing typical clinical, histologic, and ultrastructural findings are reported. In one,
gastric cancer
occurred; in the other two cases, severe polyarthritis was the only detectable internal involvement. The serine proteinases,
urokinase
and tissue-type plasminogen activator, were evaluated both with the autohistographic technique and spectrophotometric assay in lesional skin and synovia.
Urokinase
levels appeared grossly increased in the lesional synovia and moderately increased in the lesional skin. We suggest that
urokinase
, presumably released by the activated proliferating histiocytes, may play a major role in the extracellular matrix degradation leading to erosion of cartilage and adjacent bone in multicentric reticulohistiocytosis.
...
PMID:Multicentric reticulohistiocytosis. Report of three cases with the evaluation of tissue proteinase activity. 314 26
Fibrinolysis-inhibitory activity was estimated in the lysates of 21 lines of cultured human cancer cells, from which plasminogen activator activity had veen effectively eliminated by affinity chromatography. Inhibitory activity against
urokinase
varied from one line to another. Three lines of lung cancer and 1 line of urinary bladder cancer showed high inhibitory activity against
urokinase
. Two lines of lung cancer, 3 lines of
gastric cancer
, 1 line of renal cancer and 1 line of renal pelvic cancer showed moderate inhibitory activity. Since inhibitory activity against plasmin was not apparent in all the cell lines tested, this activity seemed to be directed selectively towards
urokinase
. No inhibitory activity against
urokinase
was detected in 4 lines of lung cancer, 5 lines of
gastric cancer
and 1 line of renal cancer. There was no specific correlation between the degree of inhibitory activity against
urokinase
and the histological cell types of the original tumors of the cultured cell lines.
...
PMID:Fibrinolysis-inhibitory activity of cultured human cancer cell lines. 645 67
Immunological similarities or differences between
urokinase
and plasminogen activators from 9 lines of cultured human cancer cells with varying degrees of fibrinolytic activity were examined with antibodies against human
urokinase
. The antibodies completely inhibited the fibrinolytic activity of 4 lines of
gastric cancer
, 2 lines of lung cancer, 1 line of urinary bladder cancer and 1 line of renal cancer, indicating that the plasminogen activators from these cell lines were immunologically identical to
urokinase
. In 5 out of these cell lines, immunological identity was also confirmed by double diffusion analysis. The plasminogen activator from 1 line of lung cancer was found to be immunologically dissimilar to
urokinase
by a neutralization experiment and double diffusion analysis. These findings indicate that there are at least two immunologically distinguishable forms of plasminogen activators from human cancer cells.
...
PMID:Immunological analysis of plasminogen activators from cultured human cancer cells. 677 12
The effect of fibrinolytic agents, Tissue Culture
Urokinase
(TCUK) and Urinary
Urokinase
(UUK), was investigated in a total of 146 patients with
gastric cancer
, pulmonary cancer or breast cancer who received various anti-cancer agents, mainly MMC, in combination with the fibrinolytic agents. Assessments were made according to the Koyama-Saito criteria. In order to maintain impartiality of this comparative trial, the drugs were randomly administered to the patients by a card system. The patients who died during the study were excluded from the analysis and the patients with colorectal cancer were also excluded because this disease was not included in the study protocol. As a result, 51 patients given TCUK and 50 patients given UUK (101 in total) were subjected to analyse. The response rate (CR + PR/No. of admitted patients) was 15.6% (8/51) for the TCUK group and 10.0% (5/50) for the UUK group respectively. The patients with measurable lesions in the TCUK group showed a response rate of 25.9% (7/27) and those in the UUK group, 14.3% (4/28). Side effects were observed in 52.1% of patients in the TCUK group and 47.9% in the UUK group. However, these symptoms were related to the anti-cancer agents. Neither a tendency to hemorrhage nor allergic symptoms occurred in association with the two fibrinolytic agents, TCUK and UUK. to UUK in terms of an activity to enhance the chemotherapeutic effect of anti-cancer agents and that combination use of TCUK and anti-cancer agents seems to be useful.
...
PMID:[Clinical evaluation of various antineoplastic agents combined with urokinase--a comparison between urokinase from tissue culture (TCUK) and urine-derived urokinase (UUK)]. 682 Sep 18
The prerequisite for a curative resection of metastases is their restriction to the key organs, the liver and lungs, in the sense of a limited dissemination. For long-term prognosis, the type of primary tumor as well as the radical resection of lung and liver metastases is essential. To improve the process of surgical indication and therapy of tumors, clear definitions for the terms "tumor recurrence" and "metastases" have been agreed upon. Research and clinical investigation have led to a better understanding of tumor-regulating factors, some of which are briefly described: Metastasis promoting factors include the lack of E-cadherin, which leads to a local penetration of basal membranes by tumor cells; CD44 seems to play an important role in cell-cell and cell-matrix interactions, apparently increasing the metastatic potential of tumors and reducing the long-term survival of patients. High levels of
urokinase
in primary tumors are also associated with a poorer prognosis, as well as plasminogen inactivator inhibitor PAI II, which plays a crucial role in tumor growth. Positive findings in bone marrow aspirates of patients with different malignancies, stained for cytokeratin 18, either are associated with higher recurrence rates in colon and breast cancer or can be correlated to the prognosis of patients with
gastric cancer
. Technical aspects of surgery for hepatic, pulmonary and skeletal metastases are presented and discussed with respect to curative and palliative indications.
...
PMID:Surgical treatment of tumor metastases: general considerations and results. 753 64
The
urokinase
pathway of the plasminogen activation is involved in proteolytic degradation of various tissues, including dissolution of the extracellular matrix and basement membranes during the process of cancer cell invasion. Recent studies have demonstrated that components of the plasminogen activation system have a prognostic impact in breast-, lung-, colorectal, bladder and
gastric cancer
. A number of studies, reviewed here, have focused on the role of the plasminogen activation system in different lung cancer types. There seems to be an obvious difference between the expression, localization and prognostic impact of the components of the plasminogen activation system in different lung cancer types. The differences seen could be helpful in understanding the biology of different lung cancer types, and components of the plasminogen activation system may have prognostic relevance and clinical implications in some lung cancer types, even though confirmatory studies are needed.
...
PMID:The plasminogen activation system and its role in lung cancer. A review. 760 25
We aim to elucidate the correlation between clinicopathological parameters and
uPA
and ECD expression in
gastric cancer
. Some 125 patients with primary
gastric cancer
, who were treated at the Second Department of Surgery, Kanazawa University, between 1988 and 1993, were enrolled in this study. The expression of
uPA
and ECD was evaluated by immunohistochemical staining using a anti-
uPA
and an anti-ECD monoclonal antibody. The nuclear DNA contents were measured by flow cytometry. Among 125 tumors, 42 (34%) were found to have preserved ECD expression (ECD (+)), and 83 (66%) reduced ECD expression (ECD (-)).
uPA
immunoreactivity was observed in 82 (65%) of 125 tumors. According to the expression of
uPA
and ECD status, groups of 22
uPA
(-)/ECD (+), 21
uPA
(+)/ECD (+), 17
uPA
(-)/ECD (-) and 65
uPA
(+)/ECD (-) were identified. There was a significant correlation between
uPA
(+)/ECD (-) status and depth of invasion, liver metastasis, peritoneal dissemination, lymph node metastasis, and venous invasion. Patients with
uPA
(+)/ECD (-) tumors showed the poorest prognosis and the highest rate of recurrence, as compared with the other groups of patients. No significant correlations were found between
uPA
(+)/ECD (-) status and DNA ploidy patterns, and histological type. Immunohistochemical analysis of the combination of
uPA
and ECD expression could be a useful method for the evaluation of metastasis and prognosis in
gastric cancer
patients. Our results indicate that
uPA
may have an important role in cancer infiltration and ECD in cancer infiltration and metastasis.
...
PMID:[Correlation between the expression of urokinase-type plasminogen activator, E-cadherin and malignancy in gastric cancer]. 761 74
The aim of the present paper is to elucidate the pathogenesis of gastric scirrhous carcinoma with special reference to fibrogenesis in cancer stroma and to the mode of cancer invasions. First, there are two hypotheses concerning the origin of the marked increase of collagen fibers in this type of carcinoma. One is thought to be production by fibroblasts stimulated by cancer cells; the other is synthesis by neoplastic cells. Our studies revealed that
gastric cancer
cells enhanced collagen production by fibroblasts in vitro, suggesting the contribution to the formation of stromal collagen in human gastric scirrhous cancer. However, one of four gastric scirrhous cancer cell lines, NKPS, was found to slightly from collagen fibers in the brain of the nude mouse. We also calculated the number of fibroblastic cells in gastric scirrhous and normal stroma by microscopical image analysis. The results showed that fibroblastic cells in scirrhous stroma were increased four-fold over those in normal stroma. This finding suggests that the mechanism by which fibrous stroma is produced in scirrhous carcinoma may be affected by the increased fibroblastic cells which were stimulated by many kinds of growth factors produced by cancer cells. It is also well known that the infiltrative growth and dispersion of scirrhous cancer cells within the gastric wall is very fast. To assess the mode of cancerous invasion of this carcinoma, we examined the
urokinase-type plasminogen activator
(
uPA
) activity of both types of cells (cancer cells and fibroblasts) with a coculture method. Scirrhous cancer cells enhanced production of
uPA
by fibroblasts. However, non-scirrhous
gastric cancer
cells produced much
uPA
by themselves. This finding suggests that scirrhous cancer cells can invade the gastric wall by use of
uPA
produced by enhanced fibroblasts, but that non-scirrhous cancer cells synthesize much
uPA
by themselves and can infiltrate the gastric wall.
...
PMID:[Pathogenesis and progression of scirrhous carcinoma]. 794 78
1
2
3
4
5
6
7
8
Next >>